ERBB2 and breast carcinoma: Despite the huge amount of clinical trials targeting the pathway in cancer, the only approved drug is Everolimus, an mTOR inhibitor, in combination with Exemestane for advanced hormone receptor positive (HR+)/HER2-negative (HER2−) breast cancer that progressed on endocrine therapy14, 15.